Clinical Trial Search

Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities

Primary: Progression-free Survival (PFS) of Low Grade Glioma Patients Treated With Autologous Dendritic Cells Pulsed With Autologous Tumor Lysate — 0; 1; 1; 1 participants

Primary: Maximum Tolerated Dose (MTD) (Recurrent Glioblastoma Participant Cohort)- Phase I — 3; 3; 3; 7 participants

Primary: Comparison of Overall Survival (OS) Between the Active Treatment Group (Arms 1 and 2) and the Control Group (Arm 3) — 16.9; 16.2; 20.6 months — p=0.196

Primary: Response Rate (Complete and Partial Response) — 7 Participants

Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants

Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…

Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants

Primary: Overall Survival Rate at 3 Years — 73.1 percentage of participants — p=<0.001

Primary: Response Rate

Primary: Marginal-failure Rate — 0 percentage of failure rate

Primary: Humoral and Cellular Immune Response — 3; 0; 7 participants

Primary: Overall Survival After Treatment — 15.8; 22; 18.7; 12.5 months

Primary: Dose Limiting Toxicities of EMD + RT and TMZ — 0; 0; 0 participants

Primary: Survival — 17.2 months — p=>.1

Primary: (Phase III) Overall Survival (OS) — 3.9; 3.8 years — p=0.36

Primary: Progression-free Survival

Primary: Maximum Tolerated Dose(MTD)of Temozolomide(TMZ) — 75 mg/m^2

Primary: Overall Survival (OS) — 18.3; 16.7 months of survival

Primary: Tumor-specific Cytotoxic T-cell Response — 0.496; 0.4836 10^9 cells/L

Primary: 6-month Progression-free Survival (PFS), Defined as a Patient Being Alive and Progression-free 183 Days After the Date of Registration. — 33.35; 33.3; 25 percentage of…

Primary: Number of Treatment Related Adverse Events — 0; 0; 0; 0 adverse events

Primary: Progression-free Survival at 6 Months (Stratum 1) — 1 patients

Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants

Primary: Sensitivity (SBR) — 5.49 ratio

Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients

Primary: Increase of Interferon Gamma Levels — 0 Participants

Primary: Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or Progressive Malignant Glioma — 0; 0; NA; 0 DLTs

Primary: Overall Survival — 19.1 months